2021
Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study
Jacobs R, Jurczak W, Flinn I, Grosicki S, Giannopoulos K, Wróbel T, Zafar S, Cultrera J, Kambhampati S, Danilov A, Burke J, Goldschmidt J, Beach D, Huntington S, Ibarz J, Sharman J, Siddiqi T, Brander D, Shadman M, Pagel J, Dlugosz-Danecka M, Ghosh N, Kolibaba K, Sportelli P, Miskin H, O'Connor O, Weiss M, Gribben J. Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study. Blood 2021, 138: 3726. DOI: 10.1182/blood-2021-147460.Peer-Reviewed Original ResearchSarah Cannon Research InstituteProgression-free survivalOverall response rateChronic lymphocytic leukemiaCurrent equity holderMedian progression-free survivalUndetectable minimal residual diseaseNon-infectious colitisBristol-Myers SquibbTreatment-naïveTN patientsTreatment statusAstra ZenecaSpeakers bureauKite PharmaPFS ratesMedian durationStudy drugMedian agePT patientsADC therapeuticsDay 1Primary analysisEnhanced antibody-dependent cellular cytotoxicityAntibody-dependent cellular cytotoxicity
2020
Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study
Gribben J, Jurczak W, Jacobs R, Grosicki S, Giannopoulos K, Wrobel T, Zafar S, Cultrera J, Kambhampati S, Danilov A, Burke J, Goldschmidt J, Beach D, Huntington S, Ibarz J, Sharman J, Siddiqi T, Brander D, Pagel J, Kolibaba K, Dlugosz-Danecka M, Ghosh N, Sportelli P, Miskin H, O'Connor O, Weiss M, Flinn I. Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study. Blood 2020, 136: 37-39. DOI: 10.1182/blood-2020-134783.Peer-Reviewed Original ResearchProgression-free survivalOverall response rateChronic lymphocytic leukemiaR CLLUndetectable minimal residual diseaseCurrent equity holderRefractory chronic lymphocytic leukemiaBristol-Myers SquibbTreatment-naïveDuration of responseBristol-Meyers SquibbDay 1Astra ZenecaSeattle GeneticsSpeakers bureauComplete responseGilead SciencesMaria Sklodowska-Curie National Research InstituteRelapsed/Refractory Chronic Lymphocytic LeukemiaTreatment-naive chronic lymphocytic leukemiaCycle 1Enhanced antibody-dependent cellular cytotoxicityAntibody-dependent cellular cytotoxicityAdvisory CommitteeData Safety Monitoring CommitteeCNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions
Orellana-Noia V, Reed D, Sen J, Barlow C, Malecek M, Kahl B, Spinner M, Advani R, Voorhees T, Snow A, Grover N, Ayers A, Romancik J, Liu Y, Huntington S, Chavez J, Saeed H, Lazaryan A, Raghunathan V, Spurgeon S, Ollila T, Del Prete C, Olszewski A, Ayers E, Landsburg D, Echalier B, Lee J, Kamdar M, Caimi P, Fu T, Liu J, David K, Alharthy H, Law J, Karmali R, Shah H, Stephens D, Major A, Rojek A, Smith S, Yellala A, Kallam A, Nakhoda S, Khan N, Cohen J, Portell C. CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions. Blood 2020, 136: 27-28. DOI: 10.1182/blood-2020-134798.Peer-Reviewed Original ResearchAggressive non-Hodgkin lymphomaNon-Hodgkin lymphomaGenentech/RocheDouble-hit lymphomaCNS-IPIAstra ZenecaSeattle GeneticsBristol-Myers SquibbSpeakers bureauElevated LDHRituximab eraHIV statusUS academic institutionsADC therapeuticsB cellsSignificant differencesMedian age 61 yearsIndolent non-Hodgkin lymphomaAdvisory CommitteeHigh-grade B-cellDiffuse large B-cellAnthracycline-based therapyECOG PS 0Recipients of chemotherapyAge 61 years